Shares of Pfizer dropped 1.8% to $38.51 at 13:23 EST on Tuesday, after four sequential sessions in a row of losses. The New York Stock Exchange is jumping 0.83% to $14,332.60, after two consecutive sessions in a row of losses. This seems, up until now, a somewhat positive trend exchanging session today.

Pfizer’s last close was $39.21, 11.87% under its 52-week high of $43.08.

Pfizer’s Sales

Pfizer’s sales growth is a negative 9.7% for the current quarter and a decline by 0.5% for the next. The company’s growth estimates for the current quarter and the next is a negative 9.1% and a negative 8.8%, respectively.

Pfizer’s Revenue

Year-on-year quarterly revenue growth declined by 4.3%, now sitting on 48.65B for the twelve trailing months.

Pfizer’s Stock Top and Bottom Yearly Value

Pfizer’s stock is valued at $38.51 at 13:23 EST, way below its 52-week high of $43.08 and way above its 52-week low of $26.45.

Pfizer’s Moving Average

Pfizer’s worth is above its 50-day moving average of $37.21 and above its 200-day moving average of $35.19.

Previous days news about Pfizer

Pfizer shot gets FDA advisers’ nod as agency decision nears. According to Bloomberg Quint on Thu Dec 10, “Marion Gruber (no relation to Pfizer’s William Gruber), head of the FDA’s Office of Vaccines Research and Review, said the agency is open to other approaches to gathering more data on the vaccine to support full FDA approval.”, “Pfizer’s Gruber said the company plans to submit data on 12- to 15-year-olds when it applies for full approval. ”

Moderna offers U.S. fail-safe on vaccines if Pfizer falls short. According to Bloomberg Quint on Thu Dec 10, “Existing U.S. deals with Pfizer and Moderna for 100 million doses of each company’s vaccine are only enough to inoculate a maximum of 100 million people combined. “, “Moderna Inc. could offer a fail-safe option that will allow the U.S. to get enough Covid-19 shots to inoculate most Americans if the government can’t reach an agreement to quickly buy more vaccine from Pfizer Inc., which plans to honor its contracts with other countries.”

FDA nears Pfizer decision; Australia cancels order: virus update. According to Bloomberg Quint on Fri Dec 11, “A New York state panel of public-health advisers approved a Food and Drug Administration committee’s backing for emergency use authorization of the Pfizer Inc. and BioNTech SE vaccine, Governor Andrew Cuomo said on Twitter.”, “The World Health Organization will review vaccines by Pfizer, BioNTech, Moderna and AstraZeneca over the “next couple of weeks” to determine whether to grant them emergency-use licenses, WHO Chief Scientist Soumya Swaminathan said Friday.”

Pfizer vaccine clearance to be sought in Hong Kong after FDA nod. According to Bloomberg Quint on Fri Dec 11, “While Pfizer sought emergency use authorization from the U.K. and U.S., the right to clear the vaccine with regulators in Hong Kong falls with Fosun, under a deal with BioNTech that saw the Chinese drugmaker investing $50 million in the German firm for a 0.7% stake.”, “Fosun has yet to apply for authorization for the Pfizer-BioNTech vaccine’s use in mainland China. ”

Pfizer raises quarterly cash dividend to 39 cents a share vs. 38 cents. According to MarketWatch on Fri Dec 11, “Pfizer Inc. said Friday’s its board has raised its quarterly cash dividend to 39 cents a share from 38 cents in the year-earlier period. “, “”It is expected that Viatris will begin paying a quarterly dividend in the second quarter of 2021, at which time Pfizer’s quarterly dividend will be reduced such that the combined dividend dollar amount received by Pfizer shareholders, based upon the combination of continued Pfizer ownership and approximately 0.124079 shares of Viatris which were granted for each Pfizer share in the spin-off, will equate to Pfizer’s dividend amount in effect immediately prior to the initiation of the Viatris dividend,” the company said in a statement. ”

FDA aiming for quick authorization of Pfizer covid vaccine. According to Bloomberg Quint on Fri Dec 11, “White House Chief of Staff Mark Meadows said that FDA Commissioner Stephen Hahn’s job could be on the line if his agency doesn’t soon approve Pfizer Inc.’s coronavirus vaccine, according to a person familiar with the matter.”, “Pfizer has said it plans to file with the FDA for a full approval for the shot in April.”

Pfizer vaccine cleared in U.S., a landmark in Covid-19 fight. According to Bloomberg Quint on Sat Dec 12, “Pfizer didn’t study the vaccine in pregnant or lactating women, though the FDA is leaving it up to those women as to whether they will receive the vaccine. “, “Pfizer Inc. gained emergency U.S. authorization for its Covid-19 vaccine on Friday, completing an unprecedented scientific sprint that could eventually help bring an end to a pandemic that has killed nearly 300,000 Americans.”

Mexico approves Pfizer vaccine for emergency use as covid surges. According to Bloomberg Quint on Sat Dec 12, “Mexico’s health agency Cofepris approved Pfizer’s coronavirus vaccine for emergency use, Deputy Health Minister Hugo Lopez-Gatell said at a press conference Friday night.”, “Mexico joins the U.K., Canada and the U.S. as countries that have granted emergency use of the Pfizer vaccine. ”

Pfizer says prepared to deliver first doses of Covid-19 vaccine in U.S. immediately. According to Business Insider on Sat Dec 12, “Pfizer and BioNTech said that they are confident in their ability to deliver the vaccine to people in the U.S. Their combined manufacturing network has the potential to supply globally up to 50 million vaccine doses in 2020 and up to 1.3 billion doses by the end of 2021.”, “Pfizer Inc. (PFE) and BioNTech SE (BNTX) said Friday that they will begin delivering the first doses of their COVID-19 vaccine in the U.S. immediately, with delivery fulfillment expected to be completed in 2021.”

U.S. CDC committee of independent health experts recommends vaccination with Pfizer and biontech Covid-19 vaccine for persons ages 16 years and older. According to Business Insider on Sat Dec 12, “Pfizer Disclosure Notice”, “Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted today to recommend the use of the Pfizer-BioNTech COVID-19 vaccine in people 16 years of age and older under the Emergency Use Authorization (EUA) issued by the U.S. Food and Drug Administration (FDA). ”

Pfizer May offer shots to trial volunteers who received placebo. According to Bloomberg Quint on Mon Dec 14, “Pfizer Inc. and BioNTech SE may soon allow participants in its Covid-19 vaccine trial to learn whether they received a placebo, rather than the real thing, and get the actual shot if they wish.”, “A go-ahead may allow some 19,000 people who received placebos to get Pfizer’s shot, which is in short supply. ”

US Covid-19 vaccinations to begin Monday as CDC recommends Pfizer vaccine. According to Business Insider on Mon Dec 14, “Earlier, Gen. Gustave Perna, chief operating officer of Operation Warp Speed, noted that Pfizer would move vaccine from its manufacturing facility to the UPS and FedEx hubs, and then it would go out to already identified 636 locations nationwide.”, “The CDC Director accepted the recommendation by CDC’s Advisory Committee on Immunization Practices or ACIP for vaccination with Pfizer-BioNTech COVID-19 vaccine in people 16 years of age and older. ”

Pfizer, biontech Covid-19 vaccine candidate study in Germany support safety profile. According to MarketWatch on Mon Dec 14, “”These results from the ongoing German Phase 1/2 study help illustrate the multiple arms of the immune system that are activated to fight SARS-CoV-2 by the vaccine candidate BNT162b2,” said Kathrin Jansen, head of vaccine research and development at Pfizer. “, “The study’s result come as the companies’ vaccine is being distributed for use in the U.S. Shares of Pfizer rose 1.5% in premarket trading and BioNTech’s stock gained 0.9%, as futures for the S&P 500 tacked on 0.6%.”

Pfizer, biontech report data from German phase 1/2 trial with Covid-19 vaccine candidate. According to Business Insider on Mon Dec 14, “Pfizer Inc. (PFE) and BioNTech SE (BNTX) reported additional data on neutralizing antibody and T cell responses from the phase 1/2 trial with BNT162b2 conducted in Germany. “, “BNT162b2 is an investigational COVID-19 vaccine developed by Pfizer-BioNTech. “

LEAVE A REPLY

Please enter your comment!
Please enter your name here